Ascentage Pharma Group International reported unaudited financial results for the six months ended June 30, 2026. Revenue increased 29% year-over-year to US$44.5 million (RMB302.2 million), driven by a 32.6% rise in product sales to US$41.6 million. The company posted a net loss of US$120.4 million, compared to US$82.5 million in the prior year period. Cash and bank balances decreased 23.3% to US$279.4 million due to increased research and development expenses associated with global clinical trials. Ascentage Pharma appointed Dr. Faiçal Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer. The company also removed the “B” marker from its Hong Kong Stock Exchange short name, indicating it met higher market capitalization and revenue thresholds. Ascentage Pharma is a global biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.

Ascentage Pharma Group International appointed Dr. Faiçal Miyara as Chief Business Officer to lead global business development and Jim Ziegler as Chief Commercial Officer to head US commercialization efforts. Both executives report directly to Chairman and CEO Dr. Dajun Yang. The appointments aim to strengthen the company's global expansion strategy, build a dedicated US commercial organization, and accelerate the execution of its pipeline for hematologic malignancies. Ascentage Pharma is an integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel cancer therapies.

Ascentage Pharma Group International announced on July 19, 2026, the submission of an automatic shelf registration statement on Form F-3 with the SEC to establish an at-the-market (ATM) offering program. The program allows the company to sell American depositary shares (ADSs) for an aggregate offering price of up to $200 million through sales agents Citigroup, Deutsche Bank, and BTIG. Proceeds are intended for the commercialization of Olverembatinib and Lisaftoclax, clinical trials, and general corporate purposes. The company operates in the biotechnology industry and develops drug candidates for oncology and other diseases.